» Articles » PMID: 19688839

Signaling Pathways Controlling Pluripotency and Early Cell Fate Decisions of Human Induced Pluripotent Stem Cells

Overview
Journal Stem Cells
Date 2009 Aug 19
PMID 19688839
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Human pluripotent stem cells from embryonic origins and those generated from reprogrammed somatic cells share many characteristics, including indefinite proliferation and a sustained capacity to differentiate into a wide variety of cell types. However, it remains to be demonstrated whether both cell types rely on similar mechanisms to maintain their pluripotent status and to control their differentiation. Any differences in such mechanisms would suggest that reprogramming of fibroblasts to generate induced pluripotent stem cells (iPSCs) results in novel states of pluripotency. In that event, current methods for expanding and differentiating human embryonic stem cells (ESCs) might not be directly applicable to human iPSCs. However, we show here that human iPSCs rely on activin/nodal signaling to control Nanog expression and thereby maintain pluripotency, thus revealing their mechanistic similarity to human ESCs. We also show that growth factors necessary and sufficient for achieving specification of human ESCs into extraembryonic tissues, neuroectoderm, and mesendoderm also drive differentiation of human iPSCs into the same tissues. Importantly, these experiments were performed in fully chemically defined medium devoid of factors that could obscure analysis of developmental mechanisms or render the resulting tissues incompatible with future clinical applications. Together these data reveal that human iPSCs rely on mechanisms similar to human ESCs to maintain their pluripotency and to control their differentiation, showing that these pluripotent cell types are functionally equivalent.

Citing Articles

Differentiation of CD166-positive hPSC-derived lung progenitors into airway epithelial cells.

Goh K, Lu H, Tan E, Lee Z, Wong A, Tran T Biol Open. 2024; 13(10).

PMID: 39387302 PMC: 11554259. DOI: 10.1242/bio.061729.


Recent Advances in Nanomaterials for Modulation of Stem Cell Differentiation and Its Therapeutic Applications.

Kim C, Koo K, Kim H, Kim T Biosensors (Basel). 2024; 14(8).

PMID: 39194636 PMC: 11352443. DOI: 10.3390/bios14080407.


Robust bioprocess design and evaluation of commercial media for the serial expansion of human induced pluripotent stem cell aggregate cultures in vertical-wheel bioreactors.

Borys B, Dang T, Worden H, Larijani L, Corpuz J, Abraham B Stem Cell Res Ther. 2024; 15(1):232.

PMID: 39075528 PMC: 11288049. DOI: 10.1186/s13287-024-03819-9.


Epigenetic and transcriptional regulations prime cell fate before division during human pluripotent stem cell differentiation.

Madrigal P, Deng S, Feng Y, Militi S, Goh K, Nibhani R Nat Commun. 2023; 14(1):405.

PMID: 36697417 PMC: 9876972. DOI: 10.1038/s41467-023-36116-9.


Challenges Facing the Translation of Embryonic Stem Cell Therapy for the Treatment of Cartilage Lesions.

Grogan S, Kopcow J, DLima D Stem Cells Transl Med. 2022; 11(12):1186-1195.

PMID: 36493381 PMC: 9801304. DOI: 10.1093/stcltm/szac078.